Can Bristol Myers Squibb and Pfizer protect Eliquis growth as drug pricing pressure rises?
Eliquis faces pricing pressure, but Bristol Myers Squibb and Pfizer are moving first. Direct access may become pharma’s new defence.
Imperative Care begins CLEAR-IT study as peripheral thrombectomy moves from device adoption to evidence scrutiny
Imperative Care’s CLEAR-IT study could reshape peripheral thrombectomy standards. Read why its real-world data strategy matters now.
What Boston Scientific’s $14.5bn Penumbra buyout means for stroke and clot intervention markets
Boston Scientific Corporation has announced a definitive agreement to acquire Penumbra, Inc. for approximately $14.5 billion, marking one of its largest acquisitions to date in the medical device sector. The deal, structured as approximately 73 percent cash and 27 percent stock, offers Penumbra shareholders $374 per share and is expected to close in 2026, subject […]